Central Nervous System Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030 from Publisher provides strategists, marketers and senior management with the critical information they need to assess the global central nervous system drugs market as it emerges from the Covid 19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the central nervous system drugs market- How does the market relate to the overall economy, demography and other similar markets- What forces will shape the market going forward- The Central Nervous System Drugs Market global report from Publisher answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider central nervous system drugs market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the Covid 19 virus and forecasting its growth.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of Covid 19 for all regions, key developed countries and major emerging markets.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
- The central nervous system drugs market section of the report gives context. It compares the central nervous system drugs market with other segments of the central nervous system drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, central nervous system drugs indicators comparison.
Scope
Markets Covered: 1) By Type: Analgesics; Anti-Parkinson drugs; Anesthetics; Anti-Epileptics; Other CNS drugs
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/ Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs
Companies Mentioned: Biogen Inc; F. Hoffmann-La Roche Ltd; Johnson & Johnson; Pfizer Inc; Novartis AG
Metrics Covered: Number of Enterprises; Number of Employees
Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, central nervous system drugs indicators comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Major companies in the central nervous system drugs market include Biogen Inc; F. Hoffmann-La Roche Ltd; Johnson & Johnson; Pfizer Inc and Novartis AG.
The global central nervous system drugs market is expected to grow from $125.28 billion in 2020 to $126.89 billion in 2021 at a compound annual growth rate (CAGR) of 1.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $163.05 billion in 2025 at a CAGR of 6%.
The central nervous system (CNS) drugs market consists of sales of central nervous system drugs and related services by entities (organizations, sole traders and partnerships) that manufacture central nervous system drugs that are used in the treatment of diseases affecting the brain or spinal cord. The central nervous system integrates sensory information and instructs the body to respond accordingly. The spinal cord is a channel for signals between the brain and the rest of the body. CNS disorder is a condition in which the brain and spinal cord's ability to function is affected, hence affecting the body. The market for CNS disorder drugs comprises of drugs that work in different ways depending on the type of disease by suppressing or boosting the brain activities. The central nervous system drugs market is segmented into analgesics; anti-parkinson drugs; anesthetics; anti-epileptics; and other CNS drugs.
North America was the largest region in the global central nervous system drugs market, accounting for 48% of the market in 2020. Asia Pacific was the second largest region accounting for 22% of the global central nervous system drugs market. Africa was the smallest region in the global central nervous system drugs market.
Many central nervous system drug manufacturers are collaborating with other manufacturers in the industry to share technical knowledge and improve product quality. These agreements are helping anti-epileptics drugs manufacturers broaden their products and services. For instance, in January 2017, Japan's Takeda Pharmaceuticals collaborated with New York-based biotech company Ovid Therapeutics to develop TAK-935, a drug for the treatment of rare epilepsy disorders in children. Also, Israel based D-Pharm LTD., and china based Jiangsu NHWA Pharmaceutical Co. Ltd., are co-developing DP-VPA, an anti-epileptic drug. In October 2016, UCB Pharmaceuticals signed a partnership agreement with Evotec for the research and development of drugs for nervous disorders such as epilepsy, Parkinson's and Alzheimer's diseases.
During the historic period, the growth of the central nervous system drugs market was restrained by patent expiration of branded central nervous system drugs. In general, pharmaceutical companies invest a large sum of money in the drug development process and patents. During the patency period, the company holding the patent holds exclusivity for the manufacturing and distribution of drugs. Post expiration of patency, generic versions of the drugs are manufactured by other companies with prices much lower than the original branded drugs. Overall, this negatively impacts the growth of the market in terms of value.
The central nervous system drugs market was mainly driven by rapid growth in emerging markets in the historic period. Emerging markets growth was aided by rising disposable income, stable political environment and increasing foreign investments in these countries. For instance, according to the IMF, China's GDP grew from $11 trillion in 2015 to $13.6 trillion in 2018. Additionally, according to the World Economic Outlook Reports by the IMF, emerging markets and developing economies together registered a growth of 4.0% in 2015 and this increased to 4.5% in 2018. Thus, strong economic growth boosted the demand for central nervous system drugs and this drove the market during the historic period.
Table of Contents
1. Executive Summary
2. Report Structure
3. Central Nervous System Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations
4. Central Nervous System Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products
5. Central Nervous System Drugs Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers
6. Central Nervous System Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth
7. Central Nervous System Drugs Market Trends And Strategies
8. Impact Of COVID-19 On Central Nervous System Drugs
9. Central Nervous System Drugs Market Size And Growth
9.1. Market Size
9.2. Historic Market Growth, Value ($ Billion)
9.2.1. Drivers Of The Market
9.2.2. Restraints On The Market
9.3. Forecast Market Growth, Value ($ Billion)
9.3.1. Drivers Of The Market
9.3.2. Restraints On The Market
10. Central Nervous System Drugs Market Regional Analysis
10.1. Global Central Nervous System Drugs Market, 2020, By Region, Value ($ Billion)
10.2. Global Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic And Forecast, By Region
10.3. Global Central Nervous System Drugs Market, Growth And Market Share Comparison, By Region
11. Central Nervous System Drugs Market Segmentation
11.1. Global Central Nervous System Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
Analgesics
Anti-Parkinson drugs
Anesthetics
Anti-Epileptics
Other CNS drugs
11.2. Global Central Nervous System Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
Hospital Pharmacies
Retail Pharmacies/ Drug Stores
Others
11.3. Global Central Nervous System Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
Oral
Parenteral
Others
11.4. Global Central Nervous System Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
Branded Drugs
Generic Drugs
11.5. Global Central Nervous System Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
Prescription-Based Drugs
Over-The-Counter Drugs
12. Central Nervous System Drugs Market Metrics
12.1. Central Nervous System Drugs Market Size, Percentage Of GDP, 2015-2025, Global
12.2. Per Capita Average Central Nervous System Drugs Market Expenditure, 2015-2025, Global
13. Asia-Pacific Central Nervous System Drugs Market
13.1. Asia-Pacific Central Nervous System Drugs Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
13.2. Asia-Pacific, Central Nervous System Drugs Market, 2020, By Country, Value ($ Billion)
13.3. Asia-Pacific, Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic And Forecast, By Country
13.4. Asia-Pacific, Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth And Market Share Comparison, By Country
13.5. Asia-Pacific, Central Nervous System Drugs Market Metrics
13.5.1. Per Capita Average Central Nervous System Drugs Expenditure, 2015-2025, Asia-Pacific Countries
13.5.2. Parkinson Prevalence Rate, Central Nervous System Drugs Market, Central Nervous System Drugs Market/Parkinson Prevalence Rate, 2020, Asia-Pacific Countries
13.6. Asia-Pacific Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7. Asia-Pacific Central Nervous System Drugs Market: Country Analysis
13.7.1. China Central Nervous System Drugs Market
13.7.1.1. China Central Nervous System Drugs Market Overview
13.7.1.2. China Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.1.3. China Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.2. Australia Central Nervous System Drugs Market
13.7.2.1. Australia Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.2.2. Australia Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.3. Hong Kong Central Nervous System Drugs Market
13.7.3.1. Hong Kong Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.4. India Central Nervous System Drugs Market
13.7.4.1. India Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.4.2. India Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.5. Indonesia Central Nervous System Drugs Market
13.7.5.1. Indonesia Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.5.2. Indonesia Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.6. Japan Central Nervous System Drugs Market
13.7.6.1. Japan Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.6.2. Japan Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.7. Malaysia Central Nervous System Drugs Market
13.7.7.1. Malaysia Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.8. New Zealand Central Nervous System Drugs Market
13.7.8.1. New Zealand Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.9. Philippines Central Nervous System Drugs Market
13.7.9.1. Philippines Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.10. Singapore Central Nervous System Drugs Market
13.7.10.1. Singapore Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.11. South Korea Central Nervous System Drugs Market
13.7.11.1. South Korea Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.11.2. South Korea Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.12. Thailand Central Nervous System Drugs Market
13.7.12.1. Thailand Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.13. Vietnam Central Nervous System Drugs Market
13.7.13.1. Vietnam Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14. Western Europe Central Nervous System Drugs Market
14.1. Western Europe Central Nervous System Drugs Market Overview
14.2. Western Europe, Central Nervous System Drugs Market, 2020, By Country, Value ($ Billion)
14.3. Western Europe, Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic And Forecast, By Country
14.4. Western Europe, Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth And Market Share Comparison, By Country
14.5. Western Europe, Central Nervous System Drugs Market Metrics
14.5.1. Per Capita Average Central Nervous System Drugs Expenditure, 2015-2025, Western Europe Countries
14.5.2. Parkinson Prevalence Rate, Central Nervous System Drugs Market, Central Nervous System Drugs Market/Parkinson Prevalence Rate, 2020, Western Europe Countries
14.6. Western Europe Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7. Western Europe Central Nervous System Drugs Market: Country Analysis
14.7.1. Austria Central Nervous System Drugs Market
14.7.1.1. Austria Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.2. Belgium Central Nervous System Drugs Market
14.7.2.1. Belgium Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.3. Denmark Central Nervous System Drugs Market
14.7.3.1. Denmark Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.4. Finland Central Nervous System Drugs Market
14.7.4.1. Finland Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5. France Central Nervous System Drugs Market
14.7.5.1. France Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5.2. France Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6. Germany Central Nervous System Drugs Market
14.7.6.1. Germany Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6.2. Germany Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.7. Ireland Central Nervous System Drugs Market
14.7.7.1. Ireland Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.8. Italy Central Nervous System Drugs Market
14.7.8.1. Italy Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.9. Netherlands Central Nervous System Drugs Market
14.7.9.1. Netherlands Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.10. Norway Central Nervous System Drugs Market
14.7.10.1. Norway Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.11. Portugal Central Nervous System Drugs Market
14.7.11.1. Portugal Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.12. Spain Central Nervous System Drugs Market
14.7.12.1. Spain Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.13. Sweden Central Nervous System Drugs Market
14.7.13.1. Sweden Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.14. Switzerland Central Nervous System Drugs Market
14.7.14.1. Switzerland Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.15. UK Central Nervous System Drugs Market
14.7.15.1. UK Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.15.2. UK Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15. Eastern Europe Central Nervous System Drugs Market
15.1. Eastern Europe Central Nervous System Drugs Market Overview
15.2. Eastern Europe, Central Nervous System Drugs Market, 2020, By Country, Value ($ Billion)
15.3. Eastern Europe, Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic And Forecast, By Country
15.4. Eastern Europe, Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth And Market Share Comparison, By Country
15.5. Eastern Europe, Central Nervous System Drugs Market Metrics
15.5.1. Per Capita Average Central Nervous System Drugs Expenditure, 2015-2025, Eastern Europe Countries
15.5.2. Parkinson Prevalence Rate, Central Nervous System Drugs Market, Central Nervous System Drugs Market/Parkinson Prevalence Rate, 2020, Eastern Europe Countries
15.6. Eastern Europe Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7. Eastern Europe Central Nervous System Drugs Market: Country Analysis
15.7.1. Czech Republic Central Nervous System Drugs Market,
15.7.1.1. Czech Republic Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.2. Poland Central Nervous System Drugs Market
15.7.2.1. Poland Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.3. Romania Central Nervous System Drugs Market
15.7.3.1. Romania Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.4. Russia Central Nervous System Drugs Market
15.7.4.1. Russia Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.4.2. Russia Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16. North America Central Nervous System Drugs Market
16.1. North America Central Nervous System Drugs Market Overview
16.2. North America, Central Nervous System Drugs Market, 2020, By Country, Value ($ Billion)
16.3. North America, Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic And Forecast, By Country
16.4. North America, Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth And Market Share Comparison, By Country
16.5. North America, Central Nervous System Drugs Market Metrics
16.5.1. Per Capita Average Central Nervous System Drugs Expenditure, 2015-2025, North America Countries
16.5.2. Parkinson Prevalence Rate, Central Nervous System Drugs Market, Central Nervous System Drugs Market/Parkinson Prevalence Rate, 2020, North America Countries
16.6. North America Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7. North America Central Nervous System Drugs Market: Country Analysis
16.7.1. Canada Central Nervous System Drugs Market
16.7.1.1. Canada Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.2. Mexico Central Nervous System Drugs Market
16.7.2.1. Mexico Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.3. USA Central Nervous System Drugs Market
16.7.3.1. USA Central Nervous System Drugs Market Overview
16.7.3.2. USA Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.3.3. USA Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17. South America Central Nervous System Drugs Market
17.1. South America Central Nervous System Drugs Market Overview
17.2. South America, Central Nervous System Drugs Market, 2020, By Country, Value ($ Billion)
17.3. South America, Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic And Forecast, By Country
17.4. South America, Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth And Market Share Comparison, By Country
17.5. South America, Central Nervous System Drugs Market Metrics
17.5.1. Per Capita Average Central Nervous System Drugs Expenditure, 2015-2025, South America Countries
17.5.2. Parkinson Prevalence Rate, Central Nervous System Drugs Market, Central Nervous System Drugs Market/Parkinson Prevalence Rate, 2020, South America Countries
17.6. South America Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7. South America Central Nervous System Drugs Market: Country Analysis
17.7.1. Argentina Central Nervous System Drugs Market
17.7.1.1. Argentina Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.2. Brazil Central Nervous System Drugs Market
17.7.1.1. Brazil Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.2.2. Brazil Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.3. Chile Central Nervous System Drugs Market
17.7.3.1. Chile Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.4. Colombia Central Nervous System Drugs Market
17.7.4.1. Colombia Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.5. Peru Central Nervous System Drugs Market
17.7.5.1. Peru Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.6. Venezuela Central Nervous System Drugs Market
17.7.6.1. Venezuela Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18. Middle East Central Nervous System Drugs Market
18.1. Middle East Central Nervous System Drugs Market Overview
18.2. Middle East, Central Nervous System Drugs Market, 2020, By Country, Value ($ Billion)
18.3. Middle East, Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic And Forecast, By Country
18.4. Middle East, Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth And Market Share Comparison, By Country
18.5. Middle East, Central Nervous System Drugs Market Metrics
18.5.1. Per Capita Average Central Nervous System Drugs Expenditure, 2015-2025, Middle East Countries
18.5.2. Parkinson Prevalence Rate, Central Nervous System Drugs Market, Central Nervous System Drugs Market/Parkinson Prevalence Rate, 2020, Middle East Countries
18.6. Middle East Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7. Middle East Central Nervous System Drugs Market: Country Analysis
18.7.1. Saudi Arabia Central Nervous System Drugs Market
18.7.1.1. Saudi Arabia Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.2. Israel Central Nervous System Drugs Market
18.7.2.1. Israel Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.3. Turkey Central Nervous System Drugs Market
18.7.3.1. Turkey Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.4. UAE Central Nervous System Drugs Market
18.7.4.1. UAE Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19. Africa Central Nervous System Drugs Market
19.1. Africa Central Nervous System Drugs Market Overview
19.2. Africa, Central Nervous System Drugs Market, 2020, By Country, Value ($ Billion)
19.3. Africa, Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic And Forecast, By Country
19.4. Africa, Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth And Market Share Comparison, By Country
19.5. Africa, Central Nervous System Drugs Market Metrics
19.5.1. Per Capita Average Central Nervous System Drugs Expenditure, 2015-2025, Africa Countries
19.5.2. Parkinson Prevalence Rate, Central Nervous System Drugs Market, Central Nervous System Drugs Market/Parkinson Prevalence Rate, 2020, Africa Countries
19.6. Africa Central Nervous System Drugs Market, Segmentation By Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7. Africa Central Nervous System Drugs Market: Country Analysis
19.7.1. Egypt Central Nervous System Drugs Market
19.7.1.1. Egypt Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.2. Nigeria Central Nervous System Drugs Market
19.7.2.1. Nigeria Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.3. South Africa Central Nervous System Drugs Market
19.7.3.1. South Africa Central Nervous System Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
20. Central Nervous System Drugs Market Competitive Landscape
20.1. Competitive Market Overview
20.2. Market Shares
20.3. Company Profiles
20.3.1. Biogen Inc
20.3.1.1. Company Overview
20.3.1.2. Products And Services
20.3.1.3. Strategy
20.3.1.4. Financial Performance
20.3.2. F. Hoffmann-La Roche Ltd
20.3.2.1. Company Overview
20.3.2.2. Products And Services
20.3.2.3. Strategy
20.3.2.4. Financial Performance
20.3.3. Johnson & Johnson
20.3.3.1. Company Overview
20.3.3.2. Products And Services
20.3.3.3. Strategy
20.3.3.4. Financial Performance
20.3.4. Pfizer Inc
20.3.4.1. Company Overview
20.3.4.2. Products And Services
20.3.4.3. Strategy
20.3.4.4. Financial Performance
20.3.5. Novartis AG
20.3.5.1. Company Overview
20.3.5.2. Products And Services
20.3.5.3. Strategy
20.3.5.4. Financial Performance
21. Key Mergers And Acquisitions In The Central Nervous System Drugs Market
22. Market Background: Pharmaceutical Drugs Market
22.1. Pharmaceutical Drugs Market Characteristics
22.2. Pharmaceutical Drugs Market Historic and Forecast, 2015-2020, 2020-2025F, 2030F Growth, By Segment, Value ($ Billion), Global
22.3. Global Pharmaceutical Drugs Market, 2020, By Region, Value ($ Billion)
22.4. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic And Forecast, By Region
22.5. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Segmentation By Type, Value ($ Billion)
23. Recommendations
23.1. Global Central Nervous System Drugs Market In 2025- Growth Countries
23.2. Global Central Nervous System Drugs Market In 2025- Growth Segments
23.3. Global Central Nervous System Drugs Market In 2025- Growth Strategies
24. Appendix
24.1. NAICS Definitions Of Industry Covered In This Report
24.2. Abbreviations
24.3. Currencies
24.4. Research Inquiries
24.5. The Business Research Company
25. Copyright And Disclaimer
Biogen Inc
F. Hoffmann-La Roche Ltd
Johnson & Johnson
Pfizer Inc
Novartis AG